Dergiler / Experimed / 2022 / Cilt: 12 - Sayı: 3

Increased Perforin- and IL-21-Expressing NK Cells in Patients with Early-Stage Chronic Lymphocytic Leukemia

Sayfa
225–231
Yayın Tarihi
2022-12-31
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Additionally, increased levels of IL-17 and IL-21 in total NK cell of CLL patients were obtained compared to healthy subjects.Conclusion: The findings suggest that in the early stage of CLL, increased total NK cell frequency, and elevated perforin and IL-21 levels in NK cells might have a protective impact against the progression of the disease for CLL patients.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: CD5+CD19+ cells have a low proliferation capacity and elevated expression of anti-apoptotic protein BCL-2, mostly in the G0/G1 cell phase and accumulate in the pathogenesis of chronic lymphocytic leukemia(CLL).
📊
Temel Bulgular & Veri:This study evaluated the frequency, expression of cytotoxic enzymes, and intracellular cytokine levels of NK cells in CLL patients.Materials and Methods: In this study, peripheral blood mononuclear cells were isolated from peripheral blood samples of CLL patients (n=29) and healthy controls (n=16) by density gradient centrifugation method.The frequency of the total NK cells and the intracellular levels of perforin, granzyme, interferon (IFN)-γ, interleukin (IL)-21, IL-4 and IL-17 in NK cells were investigated.Results: Elevatedtotal NK cell frequency were found in the CLL patients compared to the healthy controls, and negatively correlated with CD5+CD19+ malign B cell frequency.
💡
Sonuç & Katkı:Additionally, increased levels of IL-17 and IL-21 in total NK cell of CLL patients were obtained compared to healthy subjects.Conclusion: The findings suggest that in the early stage of CLL, increased total NK cell frequency, and elevated perforin and IL-21 levels in NK cells might have a protective impact against the progression of the disease for CLL patients.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Chronic Lymphocytic Leukemia · CLL · Natural Killer Cells

Abstract

Objective: CD5+CD19+ cells have a low proliferation capacity and elevated expression of anti-apoptotic protein BCL-2, mostly in the G0/G1 cell phase and accumulate in the pathogenesis of chronic lymphocytic leukemia(CLL). Natural killer (NK) cells have the ability to kill the intracellular pathogen-infected or cancer cells and secrete cytotoxic enzymes. This study evaluated the frequency, expression of cytotoxic enzymes, and intracellular cytokine levels of NK cells in CLL patients.Materials and Methods: In this study, peripheral blood mononuclear cells were isolated from peripheral blood samples of CLL patients (n=29) and healthy controls (n=16) by density gradient centrifugation method.The frequency of the total NK cells and the intracellular levels of perforin, granzyme, interferon (IFN)-γ, interleukin (IL)-21, IL-4 and IL-17 in NK cells were investigated.Results: Elevatedtotal NK cell frequency were found in the CLL patients compared to the healthy controls, and negatively correlated with CD5+CD19+ malign B cell frequency. Increased perforin expression was observed in patients’ total NK cells. Additionally, increased levels of IL-17 and IL-21 in total NK cell of CLL patients were obtained compared to healthy subjects.Conclusion: The findings suggest that in the early stage of CLL, increased total NK cell frequency, and elevated perforin and IL-21 levels in NK cells might have a protective impact against the progression of the disease for CLL patients.

🔖

Bu Makaleye Atıf Yap

AKBOĞA, F., HİNDİLERDEN, F., GULTURK, E., HİNDİLERDEN, İ. Y., YILMAZ, A., DENİZ, G., GELMEZ, M. Y. (2022). Increased Perforin- and IL-21-Expressing NK Cells in Patients with Early-Stage Chronic Lymphocytic Leukemia. Experimed, Cilt: 12 - Sayı: 3, 225–231. https://ajindex.com/articles/878279

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (15)

  1. Yosifov DY, Wolf C, Stilgenbauer S, Mertens D. From Biology to Therapy: The CLL Success Story. Hemasphere 2019
  2. 3(2): e175. [CrossRef] google scholar 2. Rai KR, Jain P. Chronic lymphocytic leukemia (CLL)-Then and now. Am J Hematol 2016
  3. 91(3): 330-40. [CrossRef] google scholar 3. Kay NE, Hampel PJ, Van Dyke DL, Parikh SA. CLL update 2022: A continuing evolution in care. Blood Rev 2022
  4. 100930. [CrossRef] google scholar 4. Hallek M. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. Am J Hematol 2019
  5. 94(11): 1266-87. [CrossRef] google scholar 5. Malavasi F, Deaglio S, Damle R, Cutrona G, Ferrarini M, Chiorazzi N. CD38 and chronic lymphocytic leukemia: a decade later. Blood 2011
  6. 118(13): 3470-8. [CrossRef] google scholar 6. Kucuksezer UC, Aktas Cetin E, Esen F, Tahrali I, Akdeniz N, Gelmez MY, et al. The Role of natural killer cells in autoimmune diseases. Front Immunol 2021
  7. 622306. [CrossRef] google scholar 7. Gardiner CM. NK cell metabolism. J Leukoc Biol 2019
  8. 105(6): 1235-42. [CrossRef] google scholar 8. Bi J, Tian Z. NK cell dysfunction and checkpoint immunotherapy. Front Immunol 2019
  9. [CrossRef] google scholar 9. Sportoletti P, De Falco F, Del Papa B, Baldoni S, Guarente V, Marra A, et al. NK cells in chronic lymphocytic leukemia and their therapeutic implications. Int J Mol Sci 2021
  10. 22(13). [CrossRef] google scholar 10. Beatty GL, Gladney WL. Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res 2015
  11. 21(4): 687-92. [CrossRef] google scholar 11. Yao Y, Lin X, Li F, Jin J, Wang H. The global burden and attributable risk factors of chronic lymphocytic leukemia in 204 countries and territories from 1990 to 2019: analysis based on the global burden of disease study 2019. Biomed Eng Online 2022
  12. 21(1): 4. [CrossRef] google scholar 12. Yoshino T, Tanaka T, Sato Y. Differential diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma and other indolent lymphomas, including mantle cell lymphoma. J Clin Exp Hematop 2020
  13. 60(4): 124-9. [CrossRef] google scholar 13. Chennamadhavuni A, Lyengar V, Shimanovsky A. Leukemia. In StatPearls. Treasure Island (FL)
  14. google scholar 14. Vlachonikola E, Stamatopoulos K, Chatzidimitriou A. T cells in chronic lymphocytic leukemia: A two-edged sword. Front Immunol 2020
  15. 612244. [CrossRef] google scholar 15. MacFarlane AWt, Jillab M, Smith MR, Alpaugh RK, Cole ME, Litwin S, et al. NK cell dysfunction in chronic lymphocy